ArticleFrontiers in oncology2021
RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Association of METTL14 expression with prognosis and immunotherapy in breast cancer.Translational cancer research · 2026Article
- Review of the role and potential clinical value of m6A methylation modifications in the biological process of osteosarcoma.Frontiers in genetics · 2025Review
- Modification patterns and metabolic characteristics of mHeliyon · 2024Article
- The epitranscriptome of high-grade gliomas: a promising therapeutic target with implications from the tumor microenvironment to endogenous retroviruses.Journal of translational medicine · 2023Review
- Review
- Emerging roles of m6A RNA modification in cancer therapeutic resistance.Experimental hematology & oncology · 2023Review
- A Risk Signature Consisting of Eight mCellular and molecular neurobiology · 2022Article
- RNA modification patterns based on major RNA modifications define tumor microenvironment characteristics in glioblastoma.Scientific reports · 2022Article
- The role of m6A methylation in osteosarcoma biological processes and its potential clinical value.Human genomics · 2022Review
- Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.Frontiers in immunology · 2022Article
- Development of a Novel Prognostic Model of Glioblastoma Based on m6A-Associated Immune Genes and Identification of a New Biomarker.Frontiers in oncology · 2022Article
- Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.Computational and structural biotechnology journal · 2022Review
- Identification of genes modified by N6-methyladenosine in patients with colorectal cancer recurrence.Frontiers in genetics · 2022Article
- The role and regulatory mechanism of mFrontiers in genetics · 2022Review
- The Role of m6A Regulator-Mediated Methylation Modification and Tumor Microenvironment Infiltration in Glioblastoma Multiforme.Frontiers in cell and developmental biology · 2022Article
- Roles of the mFrontiers in immunology · 2022Article
- The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.Frontiers in immunology · 2022Review
- Article
- NFrontiers in immunology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is a group of intracranial neoplasms with intra-tumoral heterogeneity. RNA N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.